Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
A team at RMIT University in Melbourne say that extremely small metal particles – which they dub ‘nanodots’ – could be ...
DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...
Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...
Siddhartha Mukherjee, oncologist and author of “The Emperor of All Maladies,” asks: What if we change what a tumor can eat?
BOSTON & SHENZHEN, China--(BUSINESS WIRE)--Signet Therapeutics, a clinical-stage biotech company leveraging organoid- and AI-driven cancer drug discovery, announced that the U.S. Food and Drug ...
FOX 13 Tampa Bay on MSN
USF researchers develop tumor-targeting cancer treatment already saving pets: Human trials could be next
USF medical engineering professors Dr. Richard Heller and Dr. Mark Jaroszeski have spent more than three decades developing a ...
No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.
News Medical on MSN
Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias
Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback